WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment

Hong Kong WinHealth Pharma Group has entered a licensing agreement with fellow Hong Kong firm Jacobson Pharma Corporation (HKG: 2633) to develop and commercialize Arsenol (oral arsenic trioxide solution) in mainland China. The therapy, developed from research at the Li Ka Shing Faculty of Medicine, University of Hong Kong, is the first prescription drug fully researched and developed by Hong Kong, China, and represents the world’s first oral arsenic trioxide formulation for acute promyelocytic leukemia (APL).

Partnership Structure

Drug Profile & Clinical Excellence

• Therapeutic Class: Oral arsenic trioxide – world’s first oral formulation of this established APL therapy
• Indication: Acute promyelocytic leukemia (APL) – rare hematologic malignancy representing 5–20% of adult AML cases
• Epidemiology: Annual incidence of 1–7.4 cases per million people globally
• Clinical Outcomes:
• Overall survival rates exceeding 97% across multiple clinical studies
• 100% five-year leukemia-free survival in first-line treatment of newly diagnosed patients
• 100% five-year overall survival in first-line treatment studies
• Regulatory Recognition: Orphan drug designations from both U.S. FDA and European EMA

Innovation Significance

Scientific Achievement

• Hong Kong Innovation Milestone: First prescription drug entirely researched and developed in Hong Kong
• Formulation Breakthrough: Transforms traditional intravenous arsenic trioxide into convenient oral administration
• Patient-Centric Design: Eliminates need for hospital-based IV infusions, enabling outpatient treatment
• Therapeutic Optimization: Maintains efficacy while improving quality of life and treatment accessibility

Clinical Impact

• Survival Revolution: Transforms APL from highly fatal to highly curable leukemia subtype
• Treatment Simplification: Oral administration reduces healthcare system burden and patient inconvenience
• Global Standard: Establishes new benchmark for APL treatment worldwide
• Rare Disease Focus: Addresses critical unmet need in orphan disease with limited therapeutic options

Strategic Implications

For WinHealth Pharma

• Premium Asset Acquisition: Secures exclusive mainland China rights to breakthrough therapy
• Oncology Portfolio Enhancement: Establishes leadership position in hematologic malignancies
• Orphan Drug Expertise: Builds capabilities in rare disease development and commercialization
• Hong Kong-China Bridge: Leverages cross-border innovation ecosystem

For Mainland China Market

• Treatment Access: Provides Chinese APL patients access to world-leading oral therapy
• Healthcare Efficiency: Reduces hospitalization requirements and associated costs
• Clinical Guidelines: Potential to become standard-of-care for APL treatment in China
• Innovation Adoption: Demonstrates China’s openness to adopting cutting-edge Hong Kong-developed therapies

Market Context

• APL Patient Population: Estimated 1,500–2,000 new APL cases annually in mainland China
• Pricing Premium: Orphan drug status and superior outcomes support premium reimbursement positioning
• Competitive Landscape: Limited competition due to specialized nature of APL treatment
• Reimbursement Pathway: National Reimbursement Drug List (NRDL) inclusion likely given clinical excellence

Next Steps

WinHealth Pharma will now pursue regulatory approval in mainland China, leveraging the drug’s established safety and efficacy profile and existing international regulatory recognitions to potentially accelerate the approval process.

Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory pathways, market opportunities, and commercial expectations for Arsenol in mainland China. Actual results may differ due to risks including regulatory decisions, competitive dynamics, reimbursement negotiations, and market adoption rates.-Fineline Info & Tech